The EEG-guided MeRT system is the first personalized, biomarker-guided neuromodulation technology to receive FDA clearance for PTSD.
Wave Neuroscience said the US Food and Drug Administration (FDA) has cleared its Magnetic EEG-guided Resonance Therapy (MeRT) system for
“This FDA clearance represents an inflection point not only for Wave Neuroscience, but for the broader evolution of mental healthcare,” Fred Walke, chief executive officer of Wave Neuroscience, said in the announcement. The company said the clearance was supported by a double-blind, randomized, controlled, multisite clinical study conducted with investigators at the Texas A&M Health Institute of Biosciences and Technology.1
Key Facts
According to the company, the study evaluated the safety and effectiveness of MeRT in patients with PTSD and showed “significant and clinically meaningful reductions” in PTSD symptom severity after treatment.1 However, the announcement did not report the sample size, eligibility criteria, comparator condition, treatment duration, primary endpoint instrument, magnitude of effect, durability of response, or adverse event rates. Those details will be important for clinicians assessing how the device may fit into existing PTSD care pathways.
MeRT is a noninvasive neuromodulation system that uses EEG-based brain activity analysis, including AI-augmented biomarker assessment, to inform individualized stimulation protocols delivered with legally marketed devices. The company said the system received FDA Breakthrough Device designation in 2024 before the current clearance for PTSD.1
The clearance arrives in a treatment area with persistent unmet need. PTSD is heterogeneous in presentation, symptom burden, comorbidities, and treatment response. In the World Mental Health Surveys, lifetime prevalence was estimated at 3.9% in the total population and 5.6% among trauma-exposed individuals, with substantial impairment among affected patients.2
Current evidence-based care relies primarily on trauma-focused psychotherapies, with pharmacotherapy used when psychotherapy is unavailable, not preferred, or insufficient. The 2023 US Department of Veterans Affairs/Department of Defense guideline recommends individual, manualized trauma-focused psychotherapies as first-line treatment and supports certain medications, including
The pharmacologic landscape has been relatively stable for years. Sertraline demonstrated efficacy vs placebo in a randomized clinical trial published in JAMA, with improvement in PTSD symptom measures in civilian patients.4 Paroxetine has also been supported by randomized, placebo-controlled data in chronic PTSD.5 Even with these options, nonresponse, partial response, adverse effects, adherence issues, and patient preference continue to shape real-world management.
For clinicians, the potential relevance of MeRT lies less in replacing established PTSD treatments and more in whether biomarker-guided neuromodulation can provide an additional option for patients with persistent symptoms. The company’s description suggests an effort to individualize treatment based on measured neurophysiology rather than applying a uniform stimulation protocol. Still, the clinical significance of that personalization will depend on peer-reviewed reporting of the pivotal study, including prespecified endpoints, sham or active comparator design, blinding integrity, subgroup performance, and safety outcomes.
The next step is likely dissemination of the trial data in a peer-reviewed format and clarification of practical implementation issues, including patient selection, treatment schedule, clinician training, integration with psychotherapy and pharmacotherapy, and payer coverage. The company also indicated plans to pursue broader clinical and regulatory strategies in other conditions involving dysregulated neural network activity, but the present clearance applies to PTSD only.1
References
